1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
HOME > ORGANIZATION
ORGANIZATION
- Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
- Market Share of Generic Drugs Based on New Calculation Method Rose to 44.9% in 3rd Quarter of FY2013: JGA
May 19, 2014
- Quality Control Essential for Preventing Disruptions in Supplies of Generic Drugs; Double-Sourcing Not Enough
May 7, 2014
- Medwatcher Calls for Making Physician Payment Disclosure Obligatory by Law
May 2, 2014
- JPMA Issues New Notification on Promotional Rules Related to Data Presented at Scientific Conferences, Lecture Meetings
May 1, 2014
- Adoption of CDISC Standards Will Be Daunting Task: JPMA Regulatory Affairs Head
April 28, 2014
- JPMA Announces New Guidelines on Support for Clinical Research
April 24, 2014
- Japan Should Stick to Current Mixed Care Scheme: Kenporen Exec Shirakawa
April 22, 2014
- JMA Pres. Yokokura Voices Opposition to Proposed Mixed Care System, Annual Drug Price Revisions
April 21, 2014
- Membership Suspension Appropriate for Novartis Pharma Involvement in SIGN Trial: JPMA
April 21, 2014
- Dainippon’s Takada to Head JPMA Public Affairs Committee
April 18, 2014
- EFPIA Poised to Present Plan for Japan-Version IMI by Year-End
April 16, 2014
- Funding for Investigator-Led Studies Should Be Based on Contracts: EFPIA Japan
April 16, 2014
- More Clinical Trial Sites Sharing Information Online: JMACCT
April 16, 2014
- NCVC Establishes Integrated Information Center to Collect Information on Cardiovascular Diseases from Around the Country
April 16, 2014
- APAC Agrees to Aim for Mutual Recognition of New Drug Review Results by 2020
April 15, 2014
- Sales by 24 Member Companies Total 136.8 Billion Yen in 2013, with 12,361 Employees: JCROA
April 15, 2014
- Rattled Confidence, Dubious Eyes on Doctors “Unfortunate”: JMA Veep
April 11, 2014
- Number of CMRs Growing Rapidly in Anticipation of Major New Product Launches: JSCOA
April 11, 2014
- DSP Pres. Tada Likely to Head JPMA, Astellas’ Hatanaka Tipped for Chief Veep
April 10, 2014
ページ
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…